Everlight Electronics That Illegally Obtained LED Technology Was Charged
13.9.2018 16:00:00 EEST | Business Wire | Press release
Seoul Semiconductor (KOSDAQ:046890), a leading global innovator of LED products and technology, has announced that the International Crimes 4 Team at the Gyeonggi Nambu Provincial Police Agency in Korea is expected to detain three individuals, “A” – a former Managing Director of Seoul Semiconductor, “B” and “C” – former employees of Seoul Semiconductor, who divulged automotive LED technology that cost KRW 560 billion and seven years in development to Everlight Electronics, a competitor of Seoul Semiconductor located in Taiwan.
The three individuals will be charged for violating the Act on Prevention of Divulgence and Protection of Industrial Technology, and the Unfair Competition Prevention and Trade Secret Protection Act, and forwarded for prosecution.
Moreover, the CEO of Everlight Electronics and Everlight itself, both liable for the technology divulgence, have been charged under the Act on Prevention of Divulgence and Protection of Industrial Technology.
A, a former Managing Director of Seoul Semiconductor, took umbrage during his salary negotiations and sought out new employment opportunities using technology illegally obtained from Seoul Semiconductor as leverage. During the course of his search, A agreed to join Everlight Electronics in Taiwan as a high-paid Vice President.
Furthermore, investigations revealed that A attempted to use the information he gleaned illicitly from Seoul Semiconductor to develop an LED product for automotive headlights. To expedite development, A offered B and C, both researcher and former subordinate of A at Seoul Semiconductor, salary increases of 200% each and new jobs at Everlight Electronics in return for technical data from Seoul Semiconductor.
B and C took out laptops from the company to show secret materials of Seoul Semiconductor to A, and browsed for the secret information using their laptops at home on weekends to avoid suspicion from their colleagues. B and C also took photos of the information and either sent them via SNS or delivered them in person at Everlight Electronics in Taiwan.
In particular, B and C learned that Seoul Semiconductor had filed an injunction lawsuit against A for prohibition of competitive transaction as he joined Everlight Electronics in Taiwan, and used aliases and fake business cards to avoid litigation. They even denied the fact they were under the employ of Everlight Electronics during the investigation.
However, facts of the case showed that B and C were offered twice their previous salaries at Seoul Semiconductor, residence fee, monthly a week-long holidays, and round-trip airfares, etc. from Everlight Electronics.
Seoul Semiconductor invests approximately 10% of its annual sales into development of LED technology. In 2011, it produced automotive LED the first in Korea. As a result of its endeavors, Seoul Semiconductor holds more than 12,000 patents, and has been listed as one of the top companies around the world in terms of Patent Power compiled by IEEE (Institute of Electrical and Electronics Engineers), a global technical professional organization for electronics and electrical based in the USA. Seoul Semiconductor is the fourth largest LED manufacturer globally. The global LED lighting market currently stands at KRW 37 trillion. However forecasts expect the sector to reach KRW 52 trillion moving forward.
Separate from this case, Seoul Semiconductor has filed lawsuits against Everlight Electronics in Taiwan for five LED patent infringements.
“We estimate that, if A, B, and C were not discovered and charged, it would have lost KRW 560 billion in research and development over a seven-year period, and encroached upon its sales which currently stands at KRW 1 trillion per year,” said Yong Tae Lee, compliance department executive vice president of Seoul Semiconductor.
“The Police will leverage all legal procedures to track down suspects who leak and divulge technology overseas, as in this case, even when said suspects flee the country. Also, it will cooperate with relevant authorities to enforce measures that will allow the Police to restrict imports/exports and prohibit entry of personnel from foreign corporations that engage in industrial espionage. Moreover, it will continue to work on recovering financial damages caused by the divulgence of technology,” said the Gyeonggi Nambu Provincial Police Agency.
|
Lawsuits for LED patent infringements against Everlight Electronics (“E”) |
||||||
| # | Case | Date & News Release | ||||
| 1 |
SSC v. E
|
May 2017 | ||||
| 2 | Feb. 2018 | |||||
| 3 | Feb. 2018 | |||||
| 4 | Jul. 2018 | |||||
| 5 |
Nichia v. E
|
Mar. 2016 |
In China, Nichia filed a patent infringement lawsuit against Everlight’s China subsidiary |
|||
| 6 | Oct. 2016 |
The Japan court rules that distributors of Everlight products infringed Nichia’s patent |
||||
| 7 | Nov. 2016 | |||||
| 8 | May 2017 |
U.S. Federal Court affirms that Everlight infringed Nichia’s patent |
||||
| 9 | Jul. 2017 |
The German court rules that Everlight’s German subsidiary infringed Nichia’s patent |
||||
| 10 |
Bridgelux v. E
|
Aug. 2017 |
In U.S., Bridgelux files a patent Litigation against Everlight for infringement of 5 patents |
|||
* As a result of a lawsuit regarding the prohibition on the change of employment, which forbids a person from joining a competitor of his/her former employer for a set period of time (1~2 years) after termination, defendant A was ordered to pay KRW 100 million for violating his Non-competition agreement and joining Everlight Electronics, and a further KRW 2 million per day if A continues employment at Everlight Electronics. (Seoul Central District Court, April 2017).
About Seoul Semiconductor
Seoul Semiconductor develops and
commercializes light emitting diodes (LEDs) for automotive, general
illumination, specialty lighting, and backlighting markets. As the
fourth-largest LED manufacturer globally, Seoul Semiconductor holds more
than 12,000 patents, offers a wide range of technologies, and mass
produces innovative LED products such as SunLike – delivering the
world’s best light quality in a next-generation LED enabling
human-centric lighting optimized for circadian rhythms; WICOP – a
simpler structured package-free LED which provides market leading color
uniformity and cost savings at the fixture level, providing high lumen
density and design flexibility; NanoDriver Series – the world’s smallest
24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED
technology developed in 2005, including all AC LED-related technologies
from chip to module and circuit fabrication, as well as multi-junction
technology (MJT); and nPola, a new LED product based on GaN-substrate
technology that achieves more than ten times the output of conventional
LEDs. UCD constitutes a high color gamut display which delivers more
than 90% NTSC. To learn more, visit www.seoulsemicon.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005429/en/
Contact information
Seoul Semiconductor Inc.
Jeonghee Kim, +82-70-4391-8311
jeonghee.kim@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
